Revolutionizing Medicare: New GLP-1 Drug Coverage Announced
The Centers for Medicare & Medicaid Services (CMS) has unveiled a groundbreaking initiative to transform access to life-changing medications for millions of Americans. Starting December 23, 2025, a new voluntary program called BALANCE will empower Medicare Part D plans and state Medicaid agencies to cover GLP-1 medications, a breakthrough in weight management and metabolic health.
GLP-1 drugs, including semaglutide (Wegovy, Ozempic, Rybelsus), tirzepatide (Mounjaro), and liraglutide, have proven to be a powerful weapon against obesity, a pervasive issue affecting over 70% of adults aged 20 and above in the U.S., according to the National Center for Health Statistics. Obesity-related health problems like diabetes, heart disease, and high blood pressure can be devastating and even fatal.
The CMS's BALANCE Model aims to address this crisis head-on. By negotiating directly with pharmaceutical manufacturers, the CMS will secure lower prices and uniform coverage terms for GLP-1 medications, ensuring equal access for Medicare and Medicaid beneficiaries nationwide. This approach focuses on guaranteed pricing, potential price caps, standardized eligibility, coverage criteria, and mandatory lifestyle support programs.
The goal is to make GLP-1 drugs more accessible for eligible Americans while keeping costs manageable for patients and taxpayers. Participation in the BALANCE Model is voluntary for all parties involved, including drug manufacturers, state Medicaid agencies, and Medicare Part D plans.
In a statement, CMS Innovation Center Director Abe Sutton emphasized the program's potential: "The BALANCE Model will empower more Americans to live healthier lives by expanding access to GLP-1s, a proven method to combat diseases like diabetes and cardiovascular issues. CMS will make GLP-1s more accessible for Medicare and Medicaid recipients through this initiative."
CMS Administrator Dr. Mehmet Oz added, "Today's announcement builds on our commitment to democratize access to weight-loss medication, which has been a challenge for many. This initiative is part of our bold plan to reform health systems and Make America Healthy Again. With BALANCE, we're combining cutting-edge science with healthy living to reduce costs while empowering individuals to take charge of their well-being."
The BALANCE program will launch in Medicaid as early as May 2026 and in Medicare Part D in January 2027. To facilitate a smooth transition, CMS will implement a temporary Medicare GLP-1 payment program starting July 2026, allowing eligible Medicare Part D enrollees to pay $50 per month for GLP-1 medications. Coverage criteria will be negotiated with manufacturers, including prior authorization requirements and participation from manufacturers and plan sponsors.
Drug manufacturers interested in participating in the BALANCE program must respond to the 'Request For Applications' (RFA) by the specified deadline. State Medicaid agencies and Medicare Part D sponsors must submit a Notice of Intent by January 8, 2026, to ensure their inclusion in this transformative initiative.
